n (%) or mean±sd | |
Patient characteristics | |
Age, years | 59.7±14.7 |
Female | 114 (76) |
Systemic sclerosis/mixed connective tissue disease | 54 (36) |
WSPH group | |
Group 1 | 78 (52.0) |
Group 2 | 23 (15.3) |
Group 3 | 22 (14.7) |
Group 4 | 15 (10.0) |
Group 5 | 12 (8.0) |
PAH-specific therapy | 108 (72.0) |
American Society of Anesthesiologists class | |
1 | 0 (0.0) |
2 | 4 (2.7) |
3 | 78 (52.0) |
4 | 67 (44.7) |
5 | 1 (0.7) |
Procedural characteristics | |
ACC/AHA risk | |
Low | 110 (73.3) |
Elevated | 40 (26.7) |
Procedure at JHH | 123 (82.0) |
Inpatient | 48 (32.0) |
Emergency | 9 (6.0) |
Duration >3 h | |
Yes | 42 (28) |
No | 106 (70.7) |
Unknown | 2 (1.3) |
Preoperative assessments within 3 months of procedure | |
PH clinic visit | 101 (67.3) |
Anaesthesia clinic visit | 32 (21.3) |
Cardiac anaesthesia review# | |
Yes | 93 (75.6) |
No | 27 (22.0) |
Unknown | 3 (2.4) |
WHO FC assessment | 94 (62.7) |
BNP/pro-BNP | 82 (54.7) |
Echocardiography | 79 (52.7) |
6MWT | 34 (22.7) |
RHC | 31 (20.7) |
WSPH: World Symposium on Pulmonary Hypertension; PAH: pulmonary arterial hypertension; ACC/AHA: American College of Cardiology/American Heart Association; JHH: Johns Hopkins Hospital; PH: pulmonary hypertension; WHO FC: World Health Organization functional class; BNP/pro-BNP: brain natriuretic peptide/pro-brain natriuretic peptide; 6MWT: 6-minute walk test; RHC: right heart catheterisation. #: only among procedures performed at JHH.